25-08-2008, 11:56
Warsaw (Puls Biznesu) - Adamed wants to buy
Polfa Tarchomin, the state-owned medicine producer and promote its insulin. Adam
Wilczega, Bioton head, has so far shared the Polish insulin market with Novo
Nordisk and Eli Lilly. But Maciej Adamkiewicz, the owner of Adamed, wants to win
quickly a big piece of the market. There is only one way to do this: he must
acquire troubled Polfa Tarchomin from the state. In a longer perspective, this
can really threaten the position of Bioton, analysts believe.